Overexpression of Bcl-2 inhibited apoptosis and increased HSP levels, and transfection with hsp70 further enhanced the immunogenicity of tumor cells, suggesting that promoting non-apoptotic cell death pathways may improve cancer immunetherapy (Melcher et al., 1998[104]). The gene discussed is BCL2; the disease is cancer.